|Day's Range||81.100 - 81.790|
|52 Week Range||66.930 - 83.580|
|PE Ratio (TTM)||30.56|
|Dividend & Yield||2.72 (3.38%)|
|1y Target Est||N/A|
Celgene stock dipped to a four-month low Monday after ozanimod failed to show a disability benefit over interferon in multiple sclerosis patients.
Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal ...